Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
History of hypersensitivity to Chinese hamster ovary (CHO) cells or other human or humanized recombinant antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to any of the components of cergutuzumab amunaleukin and atezolizumab; hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
GENERAL: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or any of the study drugs
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
This criterion applies only to the patients enrolled before August ,  and those enrolled after this date electing to receive bevacizumab; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
Patients must not have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity of Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to bevacizumab
Known hypersensitivity to Chinese hamster ovary cell products or to recombinant human or murine antibodies, or any of the treatments in this protocol
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
Known hypersensitivity to bevacizumab, Chinese hamster ovary cell products, or other recombinant human or humanized antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cells
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cells
Prior hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (Phase I and II)
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the study
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies including hypersensitivity to any component of bevacizumab
Patient must not have a known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
